<SEC-DOCUMENT>0001193125-14-162854.txt : 20140428
<SEC-HEADER>0001193125-14-162854.hdr.sgml : 20140428
<ACCEPTANCE-DATETIME>20140428160603
ACCESSION NUMBER:		0001193125-14-162854
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140424
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140428
DATE AS OF CHANGE:		20140428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RESMED INC
		CENTRAL INDEX KEY:			0000943819
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980152841
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15317
		FILM NUMBER:		14789497

	BUSINESS ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		8587462400

	MAIL ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d716984d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>FORM 8-K </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Under Section&nbsp;13 or
15(d) of </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Date of Report (Date of earliest event reported): </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>April&nbsp;24, 2014 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ResMed Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(Exact Name of Registrant as Specified in Charter) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Delaware</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>001-15317</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>98-0152841</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(State or Other Jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Incorporation)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(Commission</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">File
Number)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Identification No.)</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>9001 Spectrum Center Blvd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>San Diego, California 92123 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(Address of
Principal Executive Offices) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(858) 836-5000 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(Registrant&#146;s telephone
number, including area code) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">[&nbsp;&nbsp;&nbsp;&nbsp;]&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">[&nbsp;&nbsp;&nbsp;&nbsp;]&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">[&nbsp;&nbsp;&nbsp;&nbsp;]&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">[&nbsp;&nbsp;&nbsp;&nbsp;]&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;8.01. Other Events. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:ARIAL" ALIGN="justify">On April&nbsp;24, 2014, we announced that the ex-dividend date for holders of Chess Depositary Instruments trading on the Australian
Securities Exchange will be May&nbsp;16, 2014. This amends the ex-dividend date of May&nbsp;14, 2014 that was included in our April&nbsp;23, 2014 announcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Accordingly, the quarterly dividend of $0.25 per share will have a record date of May&nbsp;20, 2014, and be payable on June&nbsp;17,
2014. The dividend will be paid in U.S. currency to holders of ResMed&#146;s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount
in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May&nbsp;16, 2014 for both CDI holders and for common stock holders. ResMed has received
a waiver from the ASX&#146;s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May&nbsp;14, 2014 through May&nbsp;20, 2014, inclusive.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt"><U>Exhibits:</U></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt"><U>Description of Document</U></P></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">99.1</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt">Press Release dated April 24, 2014</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:ARIAL" ALIGN="justify">We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities
Exchange Act of 1934. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt">Date:&nbsp;&nbsp;&nbsp;April&nbsp;28, 2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>RESMED INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">(registrant)</P></TD></TR>


<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt">By: <U>/s/ Brett Sandercock&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt">Name: Brett Sandercock</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt">Its: Chief Financial Officer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt"><U>Exhibits:</U></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt"><U>Description of Document</U></P></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt">&nbsp;99.1</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE="font-family:ARIAL; font-size:10pt">Press Release dated April 24, 2014</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d716984dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify">


<IMG SRC="g716984g85y07.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>RESMED INC. ANNOUNCES AMENDMENT TO EX-DIVIDEND DATE</B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">SYDNEY, April&nbsp;24, 2014 &#150; ResMed Inc. (NYSE: RMD and ASX: RMD) announced today that the ex-dividend date for
holders of Chess Depositary Instruments trading on the Australian Securities Exchange will be May&nbsp;16, 2014. This amends the ex-dividend date that was included in our announcement made earlier today of May&nbsp;14, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Accordingly, the quarterly dividend of $0.25 per share will have a record date of May&nbsp;20, 2014, and be payable on June&nbsp;17, 2014. The dividend
will be paid in U.S. currency to holders of ResMed&#146;s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian
currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May&nbsp;16, 2014 for both CDI holders and for common stock holders. ResMed has received a waiver from
the ASX&#146;s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May&nbsp;14, 2014 through May&nbsp;20, 2014, inclusive.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About ResMed </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">ResMed changes lives by developing,
manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who
suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">For Investors: Further information can be obtained by contacting David Pendarvis at ResMed Inc., San Diego, at (858)&nbsp;836-5000; Brett Sandercock at
ResMed Limited, Sydney, at (+612)&nbsp;8884-2090; or by visiting the company&#146;s multilingual website at www.resmed.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Statements contained in
this release that are not historical facts are &#147;forward-looking&#148; statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements &#151; including statements regarding ResMed&#146;s
projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products &#151; are subject to risks and uncertainties, which could cause actual results to materially differ from those
projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed&#146;s periodic reports on file with the U.S. Securities&nbsp;&amp; Exchange Commission. ResMed does not undertake to update its
forward-looking statements. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">- End - </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g716984g85y07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g716984g85y07.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`8P"``P$1``(1`0,1`?_$`*,``0`"`04!`0``````
M```````("0<"!`4&"@$#`0$``00#`0```````````````0,$!@<"!0@)$```
M!@(!`P,"`P<#!0`````!`@,$!08`!P@1$@DA,1-!%"(5%E%A<8$R(PK!%QB1
MH;%"&1$``0,#`P($`P4&!P```````0`"`Q$$!2$2!C$'05%Q(F$3"(&1,D(4
M\*'!4B,5L='Q8I(S%O_:``P#`0`"$0,1`#\`]^V6ZE,(F$3"+YU_=]>G7^7O
M_+)<-M*^/[E`.I!T_BN@3FU=;UBSURE66]T^OW&X"<M4JLW98:+L-D%,WQF"
M$AWKQ%_)?W`$@?$0W<<!*'4?3+BVLKV\M7WUG%)+81_CD:#M;4T%316\MY:V
M\K(+J1D=Q)^%I(J?1;:,W%JR9OTUJJ)V%3)+9E<8I2<]065EB7-NB&"P$,F[
MD(%%T>0:H]JI!$3$#M`Y1'IU#KREQ^0AM&9&6&08QY($M#L)'4=%R%U;.G_2
MMD:;FE=OBLD_]LLP?=M=H5<)DJ$PB81,(F$3")A$PB81,(F$6(=V;UUCQXUO
M8=L[<L:-5HU83;FDY55!P\4,N]<$:,&#!BR27>R,B_=JE2101(=0YS>W0!$.
MVX[@\MRS-Q<;X[`ZYS<Q`;'HWKYO=1@`\22L=Y/RK!</PDO(\].(L/"*O>`7
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M5XK>Z]M5+8D=!BZ<-'U7H5VV'`J1+^Z1S4K5.2D#MG($71:+KF;H&ZB0O4"=
MN(R]P<O=\;QW$KZ*`X6TE#I0T$/D`-:`GIY:K9#,/:QY+^[1U_5TTKT^Y1CU
MWM_D1XN*!HS3G*)[M#FG>N0^]IB$B[G1CS<\QUC77IJ^Q2:O)FQ,59F8<+OW
MZCY-B?X2)I?,5-3M3]>SR=A@N9WEUDL!LL+.TA#BR6FYY_VB.H'VE9)9V;KQ
MCI-[6D=:^/W*]HBQ3F,7H("7U'U`0]S![AZ"("7_`*YK'V$T:?X*P+F[MC=2
MOVR%*81,(F$3")A$PB81,(N+E9=M#1DC+/2J@TC&#R2<_$3Y5?MV+91TO\29
M1ZJ*?&D/0H>X^F<HV_.FBABH?FFE?`>JH7%PRVAEN)0?E1-J3YT%31>7%[Y#
M*?Y3+JZX-[4U0_H.K-Q6E-EJ_8E4FW#V^U"V5E5U-U.8M$9(M_R63;R18\Y'
M"*7QE1(N(&$P%$X>R+GLWF.SN$9W.Q5W#?Y+'`/N+=XVPL8X>#FG?U(Z`KP)
M:]_\9WYY%=]HLY9#'X[*DQVD]NYLDVYI-"]I(8*@&NJNLX%<!J'P*UM8Z-3+
M9.WB4NEB3LMLM,^V:QJDD[:,0CXIJSBF!E6\<RC6O=VE!10ZAU#&,;^DH>=N
MYW</)=T,E;7V4C9!:VC2(H8_PC<:FKC1Q!-#KY!>K.U/:C$]I\1=8K&SRW4E
MY<B6260!KZ`;0T-;5H(U^\J>@%Z?0/;Z?7-?!K&G<VN];5]Q]IIM6K"E<7+1
M9):.>QAU5FJ3YD]9BZ9J?;OV8O&JK47<>Y*41:O4"K"9-0/4A@`<Y,>^*GRS
M2I]WQ1KI&2!S3[/)51\-JQ_PDV\3@%7JMR<V]6I^O6[?Z_)[8ZZ,M1(J0F90
MJ9M=IR*91*W>)%:E$?[@**O%Q.*7103%RK/SQ\ELO[R3:0-8`SY$0(D=2@W=
M-NOCK59?F'LS&*_O\KK6W>RC!;QM(D=2GNT&W]ZMO#V#^`?^,Q-8@-15?<(F
M$3")A$PB81,(F$5`?D[\G6Y>+N[8?3&G(*J-E6M1B+9:+#;X)S81EPG%WA&T
M'%L"/F+9M&I(-#?<..IU#J&$A.SM$1]6=C^QO'>XG&[KD&=FE#&NVQ1P.:UX
M(ZN=NZ@^`K\?%>%?J:^ISF7:SF%MQ#B,%H8C&'R/N:;7;A^$5(H!XDJ07CCT
M)Q7V'3:9S?IF@('76V[XWL?YH1I)3<A7:Y84Y21@K1(T2'DW:\?!L9Q9NJ=,
MR*8'306,F4P!W=VO^ZV=YCA,Q>=N[K*?J\):4VN;H9A0%K9M/=LT!U-2*K9'
M8/C7;3E.`L.\&%X_:XSDUX7!PC+W")X+FO=$'F@W=>@T=HK>0]@_@&:37J)?
M<(F$3"*'7-W4S+:&EU)!Y*[Q;'U#88W<\?6N/EB"NW[84K0".9-E1$C&Z)2;
M*Q*&^$S8PE[SB40'N``'L\1<30W`]L1E.E2*L^WQ]5D'&+O])EHXP+<NE]M9
MQ6-M?$T4AM:79W?J#3;G(U"R4)]::M#V)W3+@BW;6FKK2C--RI!V!LW5620E
MH\QA(L4#"`&#IZ#Z!9S1%DQCJ"2?#HNHR,++&_FMF/;+:Q$_UFU#'4\6@T=3
MU"[_`)0Z:*V!J*CHF$3")A%M1=>O:1(Z@]!,/9V]H%]?43"(!U'T]/?URNV`
MEM7D-/D>JIE[^@:"1(&N&YM6@_F(K6G[UN@]0#Z?N_9E`Z&BJIA0F$43N0W"
M7C?RBD*_,[DUXTLD[6DOM(J=;2<O`S!(PRPN%(AQ(PCUDX>11UA$P(JB8I#&
M,)>T3#US7BW</EO"HGV_';DQ6TFI::%M?.A!U6L.==FNVO<JY9?<UQ4-[>QM
MHUY<]AIY5805(2DT:K:ZJL%2:1!1M7J=9C6T1`U^'0!M&Q<>T+VHMVR0!W=.
MHB8QC"8YS&$QA$PB.8M?9&]R=V[(9!YDO9'%TCCJ7$_MZ+/<3B,;A,7#AL3!
M%;8VW:&QLC%`T#I3_/J?%=MRS79)A$PB81?B"9NH"82CT$!#T]A#T'W#V$`S
MGO+8]K/Q_'HN!9N:S=_V-/55K<;BGXY\@-B<2H.A\BK93IQ">Y"K<C-FV(;/
M2`L=[EVX.M;0<N\;H?;)10F`J#?Y3+`<A^\G:(*#<22?-F#]0*>/P\O7IZK9
MG)(H^2\7AYO+-8191MTVV..MV.;(^,-UN:4VF/\`FJ0=.BLL*;J7V]@Z>X?Z
M#TRV<*%:U!/YAM'[>2UYQ4IA%Q[V391R!W3]PBS:IE$ZKETNBW;I%_:HLN=-
M(G7]XAD/?%%&V29[6-<:"IHN<44]P_Y=M&^1P\&C<[_B/<?L"\J?.;F7S[H/
M/M]2];3]UA:S%62K-M44"`A!>539%:D$8\Z#Y\BDP43M!9]PX5(LJ*P@U+U*
M04^SKFA^6<LYA%RL6V*8YU@-*-%:_'QZ_!?7SZ?/IZ^F'DOTT?\`JN;06;\[
M/!,V]OWW?R[VTN&$UC9;ES!_191WN:=P.E>B]540L_<1<:O*-2,I):.9+2#-
M(XJ)M7RC9([ML101'O(@X,8@#Z]0#KF]V%Q8TN_$6BOK35?(>ZC@BN9(K5V^
MV;(X,=_,T$AKJ>%10KDLY*@F$3")A$PB81,(F$3"*)O+_B77.86KV&K+/>[]
MKV+C[M7KN27UW,!$3#EY7SN!38.U%$U45F+DCHW4!+W)J@10@@8@95WAP`=6
MH69\"YM><"S;\W:VUK=R_I7PM9.TO8`\4+BWI4>'P4<M!<]UEX_=RW*/6;SB
M91M-[&8:LI5WVU8G#1GL@!-(,&BZ#R9CXPKV9%**(Y6,R%VV,DY*8%?PF'+-
MM_;R$F8.A#3^>FJR[/\`:2;Y^/M^W=TSD>6R%H;B6"S:^1]M0-+FR-`-`TNI
MIY*REE-,)%LT>L'"+YB_:HOF+YHLBY:/&;@B:K9TU71.=-PW<)*%.0Y1$HE$
M!Z]!RZ`C+MH>W<?]5IUXFBEDMYHWLN8ZU:0:Z&A]"""-I]WP6-MA[UUGK*E[
M)O5DLL<I$:EKK^S7IG#OF$O.PC!BT.[!)W"LW1WS=X]`G8@FJ5/Y#B'J`=1"
MTNKNVM;62Z<\.;$*D#K]E=%D?'.*<@Y5G+#CV(M97Y')W,4%J""T323.#6AI
M-!^(T)*H"Y);=L_F(X]N(+ARRM<%8]-;!8RVRM17"9C*R\NM7GXM^UK,O'3+
M>24A9`D4]9+',T<+)`!C"(=PE()M7\@R%QSO#1?V,21R1/)<':$CI^6HZKW[
MVIXG@_HS[JQ97OA%9WUCF;"MI?Q,?/'9R-=202PE@>2!1IV-=TTZE6O>/'0^
MT]%\7=;:[WH]93^QJT,RL511\2>6J,-*2*CZ*J;&>4!<[A.(;JB0QDC@F`F^
M,@F(0!S.>)XV;'XH0Y+8_)#7=2HUZ"IUT'7PJO)7U&<\XCW#[MY'E';JW_1\
M:OBTO;&3&UTL8H9FQ#V-$I%7`T--:5)4_L[]:5]>J81,(F$3")A$PB81,(F$
M3"**O*OAYIWF708G6V[XZ7D:["65G;(I2O3;F`E6$NT;NV/5!ZBFL!FSM@_7
M16(8@@<I^H=I@`P4,A:6V38&7(.T>2S;M[W$Y5VRSLG(.,2QLO9K1\#_`)@^
M8VCZ5(`V$=!K7[U#RR^./8RO.'2'(ZC;Z>U'2^GJG4*HRT^FI85'#:$I\0K#
MEJ\28K_\E6K]B1!,[TSHAU^X##_<$2F+U+L5<G*,O&2AMFT#VU.[3[*+:>+[
MR<7A[-9+@.8P4-SS.^F>]N0VQ[@][MWS7/K\P/96C6-!81U(73^.'B;7TWR7
MY!;FO.VDMHT#=4+?:ZXUS)1#Y(TY"[#F"2<HSV`]</W+:8"+0`R#444RF#J"
M@"F(=HV.-XS^GR-Q<7\@ELIJT8*UU\ZZ:?!9%W"^IJ;EG;C"</P.*@Q>?PUQ
M:RQ7L6ULD3K>FL+FC<'/(W&M*'37JI]<;N'FAN)D188;1E':5!O:Y`DE8G"C
M^3FY.470!0C))>5F'+IZ5C&(JF(V;E,5-,#"/01'.^QF,QV&:8\=&6QNZU*T
MMW%[K]Q>[-S:77<#*27QL[=T43!''$QH=U-(P-3XNIN/FI.%2$GH'0`Z=/0>
MGT^@`4`_USM'21O'N&M5K@,+1\IC6,AIX=?\%^^4%53")A%CS:^U]>:.UW:]
ML[8M4;2-=4:+/-6VV3!E@C8.+361;F>.@;).')B?.X(0`33.<3'```<(J\/_
M`+=>*?IU_P":FK0].OJSNO7VZ^WZ5]<G1%/#1_(/27)2DH;&T)M&F;8I+AP=
MF%@I<TUEVK9\D`"M'2**1@>14DB4P"=NZ316*`@(EZ#BGW(LQ9")A$PBA=R,
M\B/"OB1;X>A<C^05+U-<9^`+:8BOV)*=6?O:^H^<QJ<H0L/#R::;=1ZS53+W
MF*81(/0.F$68]6<C]'[LT\WW_JW8T#;],N8Z?ET=ALC.VE?&,JR[YO8GRBLH
MU8N4&T.K&K@L<Z90#XC"'4,FGW(HIZU\N/CBW'L"HZKU?RNU[==A7R<;URH5
M:':6PTA/33OY!;L61G-<;M1.H5(QNXRA2`4HF$>@=<:(K&LA$PBV4E),H>/>
MRLDX39QT:S=2#]XL/:@T9,D%'+MRL?\`]4D&Z1CF'Z%*.$4:^-/-+B]S#;7!
MYQHW#7-N-*`]C8ZX.JVVFDF\$_F$WBT:T=*RT7'$46=(L%3E!(5/PDZCT`0Z
MSZ(I0Y")A$PB\\?^3/NG_;;QP.M>LWHMI??6UZ10P0*;HHXKD&J[O-C$``0,
M9(`KC9(X>W1<.OOT&?!%3]P4UUX$8'QX4BP\T;#I"R\D).GW:T7UNE;+<;;<
M.\D)6;/7*O!PU>DDD@LD7#)M"-D_@$".#]5!$H".-*?%%%/PH<T4/'?0><_*
M>X1]GF-%K0U(U_KJC$>"R#96_)"Q2\E48"/>*D.P2DX"@-GB\Z\("@LV9B=P
M&.=$A@**UJ4\N_FCHVCXKGC?N'G'9/A[)JQ,NO5VE@DV&RFE$GGZ3.)LHE6N
M+J?9,I(%R`W?.(L4A%5-0[8J1P-BOI1%)CG_`.?IGH_C]Q)O?%O6\9=M@<QJ
M0I?ZD;9SETQJFOH%K)MJQ)-)]*->QIY>Q,[BLHP$@.FK1(&JBZA_C$H"1;GC
MUS^\RU-Y#Z:U1S&X-U;86L=X.`"-VGQ@62L3*F1?<U*^L<Q8H6W6RC*1<`5Z
MFL\;NW#%P=N)C-SK&+VF:HO/EYC%I/F9Y9N64#".UE8'C7I"SH?,W,"R;-GH
M?5[BT6$@_P!1"$>WV54;*!Z>IOVX/5%(1KS'G=6?X^W&/BOJI5TZWAS)V;MK
M3D#%1*@FFTJ$CMJ6:6]5LDW,#A-:R/)5G"(#T`%"O5N@C\8]%=*(H:^*R$UC
MQ5\AFV-S;<E#/]7^/S7.UKO<)=BFDY/+WR&(QU1"P=;)^!%U(S>P;.LUBB"8
MORBD4YA`.I@#0U17>5?R[^9;D+JZ]<R>.G#S0+#B91%K#(H0EWGWSG85LK%2
M,NO87D2J-Q@7T^O$,FQ_NUHZ/(@54BA4`7%,<5]$4Y7/GTT4P\9L#SU?4UZ6
M\V6S2.I(G1"<VE]R[W7#-0>2T2G83H]Y*2PB#DE5)`4!4*Q5(G\8KF`!:=45
M4V[O+_Y>8CB9==T<A.&U$IG&/DOK^VZ[UG?:VG-5ZQ424V+69.-IED?)2=HG
M)1>(?HKBLV-(1[+[X"@9$Y!$A3-:5\$5D_\`C#Z2+K7QU.-CNV9T);>^W;A;
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MLA_(+O\`VM?GU/@+%I"`VA8(5[7#/TV[:<:LUY>MN8"R23*1*1*.81X.$7?X
M>JB!0ZXT\$5AG.:Z^+G233CAXUN6O$7E9KK2>JM;NK-K+DO-RS`VSJ"YV.0E
MI=14(2#2DTKQ"(S+Y9E/)F,L5H^:@4K102?(9\"BAIXM]L673_D]@]?<`M_;
MTW)P4@V<I;MQN=E1$E7:PRU5!TR4FKA,66L.CGA(5U67R!4H:2(A'.7CDQ2E
M1`#F*(:'1%M/&969'DG$><3F+.('?K2/&3>+%B^5ZG,2;W*ZMEW>D34,/3YV
ME;J:21@#V37``PBQ9X4]4/[5+;4YQ[775DM&^-'1M^O>OFLJ(*P!-R2L78[;
M58:-3,*:(J1,HNYF5S=##]Z=GU]!*``$75^)W$/;?(;Q.^1GD)1X&8M5S=[J
MT^\<Q\6DL^E['4]:/I/8FU4V#5N4[F3<LWMU:/U$4P.93[`W0!,'3%-*HM.M
M+1X2H+A[3Y[8;[FI9N6S:MM(.V:(I6R+%5*M/7@'!FTD\@YTM??52%J,D!Q<
M$2`ZSM,3"B+<Q^IA:4^*+-'E)XCT?0O"7Q[[7T1IS?6O>-5QO&P=E;"H&]9!
M.7OE1O-Z0UX2,:6ATR;HL8AG:JE35DHWY4TQ53$.\"'4%,"*2?FP\S?%OEWP
MZUOQ@XD_J293L5DI=BO+V7J4G58NFQ]%CP5@M?,`DD4"S$\:<7;E6!H"C1!!
MK^!0XJEZ"?)%Z[.`>FD^/G"OB_IL$/MG5'TI0F<PB(`4Y;%(PC>:LO>``'XC
M6"1<B(CZB.#Y(I>Y")A$PBZ%,ZJU?8[$TM]AUM09ZVL#,CL;1-4ZO2EB9'C5
M/FCC-)M]'+R;8S!4>Y`2*@*1O4O0<FJ+L5CK-;N$0ZK]MKT':8%]\7WL)8XE
MA-Q#SX%2+H?=1LFW=,G'PKIE.3O(/:<H"'J`8JBXJ`UYK^J0;ZL5:C4ZM5J3
M,Y/)5V`K,+#P4@=ZB5N\.^B8YDV8.S.VY`35%1,PJ$`"FZ@'3%=:HL:4CBOQ
MGUI9U+KKSCYI>CV]0ZJOZGJ>M*?`SI%%^OSG0DXV';/&IE>H]WQG+W`/KBOD
MB[GLO3NIMS1"-?VWK.A[-A&ZPN&T7?*G!VMDT<&``,X:-YMB](U7,4.@G3[3
M"'UQ5%M*#HW2^JH"1JNL]2ZVH%;F$5&\Q!4^E5RO14P@LD=!5&691<<U0E$U
M4%#$,"Y5`$AA*/H/3%47+U_5>L*G$3$!5=;T*LP5B3,E8(2OT^O0T1.I'0.U
M.G,QL='-F<FF9JH9,07(<!3,)?81#%46B,U1JV%KDM3H;6M`B:C/&.:<JL93
M:ZPKDT91--)0TM!M8Y*,D3*)(D*85DC]2D`!]`#%47,56DTRBQAX6D5&L4Z'
M4<K/5(FJP$57HQ1XX(FFN[.PB&C-J=RNFB0IU!()S%(`"/0`Q5%B%'B7Q=;7
M7_<9OQST<C?/N_S#]8I:LI2=B"2[N\)$LH6&!T60^3\7S@8%>[U[NOKBJ+,-
MLIU2OD!)U2[UBOW&L3*`-I>N6B'CYZ#E&X&`Y49"+E&SID[3(<H&*!R&[3``
MAT'%46+X;B_QKKT+'UR$X^Z4BX&*<K/8V'9:NI*,<Q?.12,X>M6I83XD7:YD
M"=ZH`"ANPO41[0Z*^B+.12%(4I2%*0I2E(4I0`I2E*'0I2@```%*'L'L&0BU
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
+)A$PB81,(F$7_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
